ACH-SITAGLIPTIN: May exceed established acceptable intake limit for NTTP.
Brand(s)
Summary
Consult your health care professional if you have any health concerns.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
ACH-SITAGLIPTIN |
ACH-SITAGLIPTIN |
DIN 02512475 |
Tablet |
SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 25 MG |
P2206573 |
ACH-SITAGLIPTIN |
ACH-SITAGLIPTIN |
DIN 02512483 |
Tablet |
SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 50 MG |
P2206574 |
ACH-SITAGLIPTIN |
ACH-SITAGLIPTIN |
DIN 02512491 |
Tablet |
SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 100 MG |
P2206575, P2206981 |
Issue
The affected lots may exceed the established acceptable intake limit for 7-nitroso-3-(trifluoromethyl)- 5,6,7,8-tetrahydro[1,2,4] triazolo-[4,3-a]pyrazine (NTTP).
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Accord Healthcare Inc.
3535 Boulevard St-Charles, Suite 704,
Kirkland, QC
H9H 5B9
Get notified
Receive notifications for new and updated recalls and alerts by category.